- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.08. | Genelux GAAP EPS of -$0.20 beats by $0.02 | 2 | Seeking Alpha | ||
| 07.08. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 07.08. | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 69 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 23.07. | Genelux stock maintains Buy rating at H.C. Wainwright amid sector news | - | Investing.com | ||
| 23.07. | Genelux: H.C. Wainwright bestätigt Kaufempfehlung trotz Rückschlag bei Konkurrenz | 1 | Investing.com Deutsch | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 21.07. | Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target | 1 | Investing.com | ||
| 07.07. | Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 161 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General... ► Artikel lesen | |
| 07.05. | Genelux GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
| 06.05. | Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates | 108 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter... ► Artikel lesen | |
| 06.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.04. | Benchmark maintains $25 target on Genelux stock, optimistic on trials | 1 | Investing.com | ||
| 31.03. | H.C. Wainwright maintains Buy on Genelux shares, target at $30 | 2 | Investing.com | ||
| 28.03. | Genelux GAAP EPS of -$0.95 misses by $0.07 | 1 | Seeking Alpha | ||
| 28.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 163 | GlobeNewswire (Europe) | - Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer - - Positive Preliminary Phase 1b/2... ► Artikel lesen | |
| 28.03. | GENELUX Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Benchmark maintains $25 target on Genelux following trial data | 1 | Investing.com | ||
| 25.03. | Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell | 1 | RTTNews | ||
| 25.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Genelux prices 3M shares at $3.50 in underwritten public offering | 3 | Seeking Alpha |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,440 | -1,46 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| QIAGEN | 40,010 | -0,45 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,430 | -1,69 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 5,826 | +0,62 % | EQS-DD: Evotec SE: Dr. Christian Wojczewski, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
27.08.2025 / 15:03... ► Artikel lesen | |
| BEAM THERAPEUTICS | 18,800 | +15,27 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| BIONTECH | 86,20 | -0,35 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,180 | +0,68 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| RECURSION PHARMACEUTICALS | 4,715 | +1,18 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| VERA THERAPEUTICS | 22,860 | +1,11 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| VALNEVA | 3,838 | +8,73 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,095 | -0,61 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 60,61 | +3,27 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| BB BIOTECH | 36,600 | +2,66 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,980 | -0,30 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 17,240 | +3,54 % | Oppenheimer initiates Tectonic Therapeutics stock with Outperform rating |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,04 % bei einem Aktienkurs von 3,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.